Generation of a Mig-6 conditional null allele

Genesis

Volumn 45, Issue 11, 2007, Pages 716-721

  Jin, Nili ^a   Gilbert, Jennifer L ^b   Broaddus, Russell R ^c   Demayo, Francesco J ^a   Jeong, Jae Wook ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Conditional ablation; Cre LoxP; Gene targeting; Mig 6; Mitogen inducible gene 6

Indexed keywords

CARRIER PROTEIN; MESSENGER RNA; MUTANT PROTEIN; PROTEIN MIG 6; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; CELL STRUCTURE; CONTROLLED STUDY; EXON; GENE EXPRESSION; GENE FUNCTION; GENETIC RECOMBINATION; HYPERPLASIA; NONHUMAN; NULL ALLELE; OSTEOARTHRITIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SKIN DISEASE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ALLELES; ANIMALS; CELL SHAPE; GENETIC ENGINEERING; MICE; MICE, KNOCKOUT; SKIN;

MUS;

EID: 38049022569     PISSN: 1526954X     EISSN: 1526968X     Source Type: Journal    
DOI: 10.1002/dvg.20348     Document Type: Article

References (19)

1. Aguirre P, Scully RE, Wolfe HJ, DeLellis RA. 1984. Endometrial carcinoma with argyrophil cells: A histochemical and immunohistochemical analysis. Hum Pathol 15:210-217.
2. Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S, Lucini F, Ingvarsson S, Segatto O. 2005. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to herceptin. Oncogene 24:4540-4548.
3. Deligdisch L, Cohen CJ. 1985. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 56:1452-1455.
4. Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, Amann K, Sommergruber W, Kraut N, Ullrich A, Fassler R, Klein R. 2006. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 12:568-573.
5. Fujii T, Dracheva T, Player A, Chacko S, Clifford R, Strausberg RL, Buetow K, Azumi N, Travis WD, Jen J. 2002. A preliminary transcriptome map of non-small cell lung cancer. Cancer Res 62:3340-3346.
6. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. 2000. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 60:4894-4906.
7. Lee KL, Isham KR, Stringfellow L, Rothrock R, Kenney FT. 1985. Molecular cloning of cDNAs cognate to genes sensitive to hormonal control in rat liver. J Biol Chem 260:16433-16438.
8. Lewandoski M, Wassarman KM, Martin GR. 1997. Zp3-cre, a transgenic mouse line for the activation or inactivation of loxP-flanked target genes specifically in the female germ line. Curr Biol 7:148-151.
9. Makkinje A, Quinn DA, Chen A, Cadilla CL, Force T, Bonventre JV, Kyriakis JM. 2000. Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress. J Biol Chem 275:17838-17847.
10. Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC. 1993. Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci USA 90:8424-8428.
11. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T, Takahashi T, Takahashi T. 1998. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 58:1380-1383.
12. Rodriguez CI, Buchholz F, Galloway J, Sequerra R, Kasper J, Ayala R, Stewart AF, Dymecki SM. 2000. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet 25:139-140.
13. Saarikoski ST, Rivera SP, Hankinson O. 2002. Mitogen-inducible gene 6 (MIG-6), adipophilin and tuftelin are inducible by hypoxia. FEBS Lett 530:186-190.
14. Tseng RC, Chang JW, Hsien FJ, Chang YH, Hsiao CF, Chen JT, Chen CY, Jou YS, Wang YC. 2005. Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. Int J Cancer 117:241-247.
15. van Laar T, Schouten T, van der Eb AJ, Terleth C. 2001. Induction of the SAPK activator MIG-6 by the alkylating agent methyl methanesulfonate. Mol Carcinog 31:63-67.
16. Wick M, Burger C, Funk M, Muller R. 1995. Identification of a novel mitogen-inducible gene (mig-6): Regulation during G1 progression and differentiation. Exp Cell Res 219:527-535.
17. Yagi T, Nada S, Watanabe N, Tamemoto H, Kohmura N, Ikawa Y, Aizawa S. 1993. A novel negative selection for homologous recombinants using diphtheria toxin A fragment gene. Anal Biochem 214:77-86.
18. Zhang YW, Staal B, Su Y, Swiatek P, Zhao P, Cao B, Resau J, Sigler R, Bronson R, Vande Woude GF. 2007. Evidence that MIG-6 is a tumor-suppressor gene. Oncogene 26:269-276.
19. Zhang YW, Su Y, Lanning N, Swiatek PJ, Bronson RT, Sigler R, Martin RW, Vande Woude GF. 2005. Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proc Natl Acad Sci USA 102:11740-11745.